Early Administration of Tirofiban in High-risk Patients with Non-ST Elevation Acute Coronary Syndrome Referred for Percutaneous Coronary Intervention

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-10000777

Enrollment

Unknown

Registered

2010-02-04

Start date

2010-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high-risk non–ST-segment elevation acute coronary syndrome

Interventions

Group A:Early administration of tirofiban

Group B:Downstream tirofiban

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. High-risk non–ST-segment elevation acute coronary syndrome (ACS) patients treated with percutaneous coronary intervention (PCI); 2. TIMI score >=3; 3. Aged from 18 to 75; 4. With the informed consent signed.

Exclusion criteria

Exclusion criteria: 1. Severe high-risk patients need to be treated with CABG; 2. Definite or possible pregnancy ; 3. High-risk haemorrhage; 4. Thombolysis in 48 hours; 5. Treated with GPIIb/IIIa receptor inhibitor in 14 days; 6. Treated with warfarin; 7. Significant other cardiac disease; 8. Hypersusceptibility for aspirin or heparin; 9. Severe hemodynamic impairment or cardiogenic shock; 10. Inferior compliance with investigate; 11. Severe abnormity of clinic examination; 12. Recruited for other clinic trial during past 4 weeks.

Design outcomes

Primary

Measure	Time frame
TMB;	—

Secondary

Measure	Time frame
MACE event;	—

Countries

China

Contacts

Public ContactYong Huo

huoyong@263.net.cn+86 10 66511764

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026